<DOC>
	<DOC>NCT02587975</DOC>
	<brief_summary>This study is designed to measure the effect of evogliptin on bone metabolism in healthy volunteers.</brief_summary>
	<brief_title>Effect of Evogliptin on Bone Metabolism in Human</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Postmenopausal healthy women (at least 5 years) BMI 18~30 kg/m2 Presence or history of hypersensitivity or allergic reactions to any drug Clinically relevant abnormal medical history or present disease Presence or history of drug abuse Participation in other clinical trial within 2 months before dose. Bood donation during 2 months or apheresis during 1 month before the study. Use of a prescription medicine, herbal medicine within 2 weeks or overthecounter medication or vitamin substances within 1 week before dose. Use of any drug which can affect bone metabolism such as sex hormones or their receptor related medicine, calcitonin or parathyroid hormone related medicine, systemic corticosteroid, bisphosphate, or etc. Smoking of more than 10 cigarettes/days within 3 months before first dose. Use of alcohol over 21 units/weeks Subject judged not eligible for study participation by investigator.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>